CALGARY, AB and SAN DIEGO, CA, Aug. 1,
2017 /PRNewswire/ - Oncolytics Biotech® Inc.
(Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) will present at
the Canaccord Genuity 37th Annual Growth
Conference. The presentation, by Dr. Matt Coffey, President & CEO of Oncolytics,
will take place at 9:00 am ET, on
Thursday, August 10, 2017 in the Hong
Kong Room at the Intercontinental Hotel. The conference takes place
on August 9th & 10th in
Boston, MA.
A live audio link to the webcast session will be available on
the Company's website at
http://www.oncolyticsbiotech.com/investor-centre/presentations. It
is recommended that listeners log on 10 minutes in advance of a
live session to register and download any necessary software. An
audio replay will be accessible approximately two hours following
the presentation on the Oncolytics website.
About Oncolytics Biotech Inc.
Oncolytics is a
biotechnology company developing REOLYSIN®, an
immuno-oncology viral-agent, as a potential treatment for a variety
of tumor types. The compound induces selective tumor lysis and
promotes an inflamed tumor phenotype through innate and adaptive
immune responses to treat a variety of cancers. Oncolytics'
clinical development program emphasizes three pillars: chemotherapy
combinations to trigger selective tumor lysis; immuno-therapy
combinations to produce adaptive immune responses; and immune
modulator (IMiD) combinations to facilitate innate immune
responses. Oncolytics is currently planning its first
registration study in breast cancer, as well as studies in
combination with checkpoint inhibitors and IMiD/targeted therapies
in solid and hematological malignancies. For further
information about Oncolytics, please
visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements,
within the meaning of Section 21E of the Securities Exchange Act of
1934, as amended. Forward-looking statements, including the
Company's belief as to the potential of REOLYSIN®
(pelareorep) as a cancer therapeutic; the Company's expectations as
to the success of its research and development programs in 2017 and
beyond, the Company's planned operations, the value of the
additional patents and intellectual property; the Company's
expectations related to the applications of the patented
technology; the Company's expectations as to adequacy of its
existing capital resources; the design, timing, success of planned
clinical trial programs; and other statements related to
anticipated developments in the Company's business and technologies
involve known and unknown risks and uncertainties, which could
cause the Company's actual results to differ materially from those
in the forward-looking statements. Such risks and uncertainties
include, among others, the availability of funds and resources to
pursue research and development projects, the efficacy of REOLYSIN
as a cancer treatment, the success and timely completion of
clinical studies and trials, the Company's ability to successfully
commercialize REOLYSIN, uncertainties related to the research and
development of pharmaceuticals, uncertainties related to the
regulatory process and general changes to the economic environment.
Investors should consult the Company's quarterly and annual filings
with the Canadian and U.S. securities commissions for additional
information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned against placing
undue reliance on forward-looking statements. The Company does not
undertake to update these forward-looking statements, except as
required by applicable laws.
SOURCE Oncolytics Biotech Inc.